

# Biologic Utilisation Patterns: Data From The International Severe Asthma Registry (ISAR)

Andrew Menzies-Gow<sup>1</sup>, Eileen Wang<sup>2,3</sup>, Mari-anne Rowlands<sup>4</sup>, Marianna Alacqua<sup>5</sup>, Mona Al-Ahmad<sup>6</sup>, Lakmini Bulathsinhala<sup>4</sup>, Victoria A. Carter<sup>4</sup>, Isha Chaudhry<sup>4</sup>, Tuck Seng Cheng<sup>4</sup>, Borja G. Cosio<sup>7</sup>, Neva Eleangovan<sup>4</sup>, J. Mark FitzGerald<sup>8</sup>, Liam G. Heaney<sup>9</sup>, Mark Hew<sup>10,11</sup>, Naeimeh Hosseini<sup>4</sup>, David J. Jackson<sup>12</sup>, Maria Kallieri<sup>13</sup>, Désirée Larenas-Linnemann<sup>14</sup>, Stelios Loukides<sup>13</sup>, Njira Lugogo<sup>15</sup>, Ruth B. Murray<sup>4</sup>, Andriana I. Papaioannou<sup>13</sup>, Luis Perez-de-Llano<sup>16</sup>, Celeste M. Porsbjerg<sup>17</sup>, Linda M. Rasmussen<sup>18</sup>, Johannes Schmid<sup>19</sup>, Trung N. Tran<sup>20</sup>, Charlotte S. Ulrik<sup>21</sup>, John W. Upham<sup>22</sup>, David B. Price<sup>4,23,24</sup>

<sup>1</sup>UK Severe Asthma Network and National Registry, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom; <sup>2</sup>Division of Allergy & Clinical Immunology, Department of Medicine, National Jewish Health, Denver, CO, USA; <sup>3</sup>Division of Allergy & Clinical Immunology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA; <sup>4</sup>Optimum Patient Care, Cambridge, United Kingdom; <sup>5</sup>AstraZeneca, Cambridge, United Kingdom; <sup>6</sup>Al-Rashed Allergy Center, Ministry of Health, Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait, Kuwait; <sup>7</sup>Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain; <sup>8</sup>Centre for Lung Health, Vancouver, Canada; <sup>9</sup>UK Severe Asthma Network and National Registry & Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland; <sup>10</sup>Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, Australia; <sup>11</sup>Public Health and Preventive Medicine, Monash University, Australia; <sup>12</sup>UK Severe Asthma Network and National Registry, Guy's and St Thomas' NHS Trust and Division of Asthma, Allergy & Lung Biology, King's College London, London, United Kingdom; <sup>13</sup>2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece; <sup>14</sup>Directora Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Ciudad de México, Mexico; <sup>15</sup>Department of Medicine, University of Michigan, Ann Arbor, MI, United States; <sup>16</sup>Department of Respiratory Medicine, Hospital Universitario Lucus Augusti, Lugo, Spain; <sup>17</sup>Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark; <sup>18</sup>Allergy Clinic, Department of Dermato-Allergology, Gentofte Hospital, Copenhagen, Denmark; <sup>19</sup>University Hospital of Aarhus, Aarhus, Denmark; <sup>20</sup>AstraZeneca, Gaithersburg, MD, USA; <sup>21</sup>Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark; <sup>22</sup>Diamantina Institute & PA-Southside Clinical Unit, The University of Queensland, Brisbane, Australia; <sup>23</sup>Observational and Pragmatic Research Institute, Singapore, Singapore; <sup>24</sup>Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.

## Introduction

### Rationale

- There is a paucity of literature on both the frequency and patterns of biologic use after biologic prescription taking into account documented inter-country differences in health care system and biologic availability.<sup>1-3</sup>

### Objective

- To describe the frequency of biologic treatment and patterns of biologic use in a global real-life severe asthma cohort.

## Methods

### Data source

- Historical cohort study using data extracted from the International Severe Asthma Registry (ISAR) on 1 Sept 2019.
  - ISAR is a multinational, observational epidemiologic data repository, containing data on patients with severe asthma aged ≥18 years on GINA 2018 Treatment Step 5 or with uncontrolled asthma on GINA Step 4.

### Patients

- Enrolled from 11 ISAR countries and providing data from January 2015 to September 2019 (Table 1).
- Treated with anti-IgE (omalizumab), anti-IL-4R (dupilumab) or anti-IL-5/5R (mepolizumab, reslizumab, benralizumab).

### Country-specific biologic questionnaire

- Information on country-specific biologic licensing, reimbursement, prescribing and stopping rules/guidelines was collected from these 11 countries using a semi-structured online questionnaire.
  - Time for safety or efficacy was defined as the length of time a country used to determine if a patient was responding adequately to a biologic.

### Analyses

- Patient biologic utilization patterns were described for the total population and for each country (stratified by length of time when ≥2 biologics were available) as:
  - Continued:** patients on a single biologic from date of biologic initiation, to point of data extraction (1 Sep 2019), with ≥6 months of follow-up data, which indicated that the patient had neither stopped nor switched their initiation biologic.
  - Switched:** patients who used ≥1 biologic during follow-up, with no restriction on time between biologics.
  - Stopped:** patients who stopped their first and only biologic, with no time criterion.
- Switch patterns were also investigated for all patients who switched biologic at least once and for those who switched multiple times.

## Results

### Country specific biologic questionnaire (Table 1)

- All countries had ≥2 biologics available at the time of data extraction (September 2019).
- Omalizumab and mepolizumab were available in all 11 countries.
- Benralizumab (81.2%), reslizumab (63.6%), and dupilumab (54.5%) were available in most countries.
- Overall, the majority (8/11) of countries reported time of efficacy assessment being at 4–12 months.

Table 1: Number and classes of biologics available in 11 ISAR countries studied

Number of Biologics	Biologic	Country
5	omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab	USA, DK
4	omalizumab, mepolizumab, benralizumab, dupilumab	JP, KW, IT, ESP, CAN
4	omalizumab, mepolizumab, reslizumab, benralizumab	UK
3	omalizumab, mepolizumab, benralizumab,	BG
3	omalizumab, mepolizumab, reslizumab	SK
2	omalizumab, mepolizumab	GR


Legend: Ig: Immunoglobulin; IL: interleukin; ISAR: international Severe Asthma Registry; BG: Bulgaria; CAN: Canada; DK: Denmark; ESP: Spain; GR: Greece; IT: Italy; JP: Japan; KW: Kuwait; SK: South Korea; UK: United Kingdom; USA: United States of America \*as of 30th Sept 2019

## Results

### Patterns of biologic use: total population

- A total of 2208 patients with severe asthma managed in specialist asthma centers from around the world were included.
- Of these patients, the majority (75.4%) continued their biologic.
- A small proportion of patients stopped (13.5%) or switched (9.5%) biologic during the course of follow-up (Figure 1).

Figure 1: Patient flow diagram of pattern of biologic use



Legend: Bx: biologic; ISAR: International Severe Asthma Registry  
7 out of 209 switchers did not have sufficient data to inform order of biologic switch  
\*insufficient follow-up time to ascribe a pattern of use and were deemed 'new users' and excluded from subsequent analysis.

### Patterns of biologic use: individual countries

- Japan and the USA had the highest proportion of stopped users, whereas SK had the highest proportion of biologic switchers, although absolute numbers were low (Table 2).
- Countries could be categorized according to ratio of switchers to stoppers
  - Higher proportion of stoppers to switchers: USA, UK, & ES
  - Higher proportion of switchers to stoppers: KW, BG, CN, DK, SK, GR
  - Equal proportion of stoppers & switchers: JN & IT

Table 2: Country-specific biologic utilization groups, stratified by length of time with ≥2 biologics available

Time with ≥2 biologics available	Country	Continued	Switched	Stopped
<b>N (%)</b>	ISAR (n=2171)	1664 (76.7)	209 (9.6)	298 (13.7)
<b>2 years</b>	Japan(n=17)	11 (64.7)	3 (17.7)	3 (17.7)
<b>3 years</b>	Kuwait (n=143)	123 (86.0)	18 (12.6)	2 (1.4)
<b>4 years</b>	Bulgaria (n=30)	27 (90.0)	2 (6.7)	1 (3.3)
	Canada (n=58)	47 (81.0)	8 (13.0)	3 (5.2)
	Denmark (n=132)	112 (84.9)	20 (15.2)	0 (0.0)
	(4 year strata Total)	186 (84.6)	30 (13.6)	4 (1.8)
	4 year strata Average	62 (84.5)	10 (13.6)	1.33 (1.8)
<b>5 years</b>	USA (n=914)	575 (62.9)	112 (12.3)	227 (24.8)
	UK (n=263)	236 (86.4)	5 (2.5)	22 (11.1)
	S. Korea (n=5)	3 (60.0)	2 (40.0)	0 (0.0)
	Greece (n=10)	9 (90.0)	1 (10.0)	0 (0.0)
	Italy (n=360)	349 (96.9)	6 (1.7)	5 (1.4)
	Spain (n=199)	172 (86.4)	5 (2.5)	22 (11.1)
	5 year strata Total	1341(75.1)	156 (8.7)	289 (16.2)
	5 year strata Average	223.5 (75.1)	26 (8.7)	48.2 (16.2)

### Switch patterns

- Overall 209 patients switched biologic; of those 202 had sufficient data (Figure 2).
  - 179/202 (88.6%) switched biologic only once and 23/202 (11.4%) switched more than once.
- Of the first biologic switches, the most common patterns were going from omalizumab to mepolizumab (n=101), followed by going from mepolizumab to benralizumab (n=35).
- Of patients who switched more than once (n=23), most switched twice (n=20/23; 87.0%) (Figure 3).
  - The most common multi-switch was from omalizumab to mepolizumab to benralizumab (n=8/23; 34.8%).

Figure 2: Distribution of first biologic switches among all patients who switched (n=202)





Figure 3: Distribution of second and third switches among individual switching more than once (n=23)



## Conclusions

- Although the majority of severe asthma patients managed around the world continue with their first prescribed biologic therapy, a minority either stop (13.5%) or switch (9.5%) therapy.
- Of those that change biologic, most switch from anti-IgE to an anti-IL-5/5R biologic.
- Inter-country variation exists in biologic usage pattern.
- More research is needed to discover and better understand the influence of country-specific factors (e.g. reimbursement, availability, guidelines) on our findings.

## References

- GINA 2019. Difficult-To-Treat & Severe Asthma in adolescent and adult patients. Available from: <https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf>
- Busse. *Allergol Int.* 2019;68:158-166
- Pavord et al. *Eur Respir Rev.* 2019;28:190054.

## Acknowledgments

ISAR is conducted by the Observational & Pragmatic Research Institute (OPRI) and co-funded by OPC Global and AstraZeneca. Presenter's conflict of interest disclosure: Andrew N. Menzies-Gow has attended advisory boards for AstraZeneca, GlaxoSmithKline, Novartis, Sanofi and Teva, and has received speaker fees from AstraZeneca, Novartis, Roche, Teva and Sanofi. He has participated in research with AstraZeneca for which his institution has been remunerated and has attended international conferences with Teva. He has had consultancy agreements with AstraZeneca, Sanofi, and Vectura.

